Nemiralisib

Nemiralisib

SCHEMBL18281136

CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1.O=C(O)c1ccccc1

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PIK3CD

The experimentally established mechanism targets of Nemiralisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PIK3CD known ✓ O00329 12/20 0.85
PIK3CB P42338 10/20 0.85
PIK3CA P42336 8/20 0.85
PIK3CG P48736 7/20 0.85
PIM1 P11309 2/20 0.43
GSK3B P49841 2/20 0.43
PIK3R2 O00459 1/20 0.38
PRKCQ Q04759 1/20 0.36
PRKCD Q05655 1/20 0.36
MAPK14 Q16539 1/20 0.34
FTO Q9C0B1 1/20 0.34
HPGDS O60760 1/20 0.34
GYS1 P13807 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nemiralisib SCHEMBL18281137 0.93 PIK3CD (0.97) PIK3CDPIK3CBPIK3CAPIK3CGPIM1
Nemiralisib SCHEMBL109919 0.93 PIK3CD (1.00) PIK3CDPIK3CBPIK3CAPIK3CGPIM1
Nemiralisib SCHEMBL29493085 0.93 PIK3CD (1.00) PIK3CDPIK3CBPIK3CAPIK3CGPIM1
Nemiralisib SCHEMBL29356978 0.93 PIK3CD (1.00) PIK3CDPIK3CBPIK3CAPIK3CGPIM1
Nemiralisib SCHEMBL659144 0.92 PIK3CD (0.98) PIK3CDPIK3CBPIK3CAPIK3CGPIM1
Nemiralisib SCHEMBL111259 0.92 PIK3CD (0.98) PIK3CDPIK3CBPIK3CAPIK3CGPIM1
SCHEMBL17255824 0.87 PIK3CD (0.88) PIK3CDPIK3CBPIK3CAPIK3CGPIM1
Nemiralisib SCHEMBL15051783 0.86 PIK3CD (0.82) PIK3CDPIK3CBPIK3CAPIK3CGPIM1
Hydrochloric Acid SCHEMBL17255819 0.86 PIK3CD (0.87) PIK3CDPIK3CBPIK3CAPIK3CGPIM1
SCHEMBL20212531 0.83 PIK3CD (0.64) PIK3CDPIK3CBPIK3CAPIK3CGPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155334-A1 NOVEL PROCESSES GLAXOSMITHKLINE IP DEV LTD (GB) 2018-06-07 US claimed
EP-3303329-A1 PROCESSES TO MAKE INDAZOLE DERIVATIVES GlaxoSmithKline Intellectual Property Development Limited (GB) 2018-04-11 EP claimed
WO-2016193255-A1 PROCESSES TO MAKE INDAZOLE DERIVATIVES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-12-08 WO claimed
CN-107660204-B Method for producing indazole derivative 葛兰素史克知识产权开发有限公司 2021-04-13 CN disclosed
EP-3303329-B1 PROCESSES TO MAKE INDAZOLE DERIVATIVES GLAXOSMITHKLINE IP DEV LTD (GB) 2019-09-18 EP disclosed
US-10266525-B2 Processes for preparing 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-04-23 US disclosed
US-20180155334-A1 NOVEL PROCESSES GLAXOSMITHKLINE IP DEV LTD (GB) 2018-06-07 US disclosed
EP-3303329-A1 PROCESSES TO MAKE INDAZOLE DERIVATIVES GlaxoSmithKline Intellectual Property Development Limited (GB) 2018-04-11 EP disclosed
WO-2016193255-A1 PROCESSES TO MAKE INDAZOLE DERIVATIVES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155334-A1 NOVEL PROCESSES CYP4A11, CYP4F11, CYP4F3 PIK3CD 758/4885PIK3CB 885/4885PIK3CA 677/4885
US-10266525-B2 Processes for preparing 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole IPO4, CYP3A4, CYP4B1 PIK3CD 700/4885PIK3CB 721/4885PIK3CA 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.